Drug intelligence / Profile preview

NEO-201 CAR-NK

Development stage: Preclinical
Lead developer: Precision Biologics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

NEO-201 CAR-NK is an investigational chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Precision Biologics for the treatment of solid and hematological malignancies. The therapy utilizes natural killer cells engineered with a CAR derived from the NEO-201 humanized monoclonal antibody, which specifically targets truncated O-glycans (core 1 O-glycans) found on CEACAM5 and CEACAM6 proteins. These truncated glycans are tumor-associated antigens that are highly expressed on various human carcinoma cells but are absent on most normal tissues. By combining the innate anti-tumor activity of NK cells with the precise targeting of the NEO-201 antibody, this therapy aims to provide a potent and selective treatment for cancers expressing these specific glycan epitopes.

Other names: NEO-201 Engineered (CAR-NK)

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)CEACAM6

Beyond the preview

Go deeper on NEO-201 CAR-NK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEO-201 CAR-NK.

Explore the full profile